SLNO DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Soleno between March 26, 2025 and November 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - April 14, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO) and reminds investors of the May 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the Soleno Phase 3 clinical trial program for DCCR had systematically downplayed, misrepresented, and/or concealed significant evidence of safety concerns potentially related to the administration of DCCR, including issues related to excess fluid retention in clinical trial participants; (2) as a result, the administration of DCCR to treat hyperphagia in individuals with PWS posed materially greater safety risks than disclosed by Soleno or its executives; and (3) consequently, DCCR had materially lower commercial viability and undisclosed risks related to the likelihood of significant and widespread adverse events after its commercial launch, including risks related to patient discontinuation rates, lower patient adoption, prescriber reluctance, adverse regulatory action, and potential reputational and legal fallout.

On August 15, 2025, Scorpion Capital LLC published a report critical of Soleno Therapeutics, Inc., its drug candidate DCCR, and the company's Phase 3 clinical trial program. The report alleged significant concerns regarding the drug's safety, efficacy, and clinical trial data. On this news, the price of Soleno common stock declined from a high of more than $77 per share on August 14, 2025 to close at approximately $68 per share on August 18, 2025, a decline of nearly 12% over two trading days.